Cardurion Announces Late-Breaking Phase 2 Tovinontrine Results in Heart Failure
Burlington, Mass. – August 27, 2026 Cardurion Pharmaceuticals announced that it will present late-breaking results from two Phase 2...
kidney health
Advertisement
MBX Biosciences Doses First Patient in Phase 3 oPTimize Trial of Canvuparatide
Carmel, Indiana and Burlington, Massachusetts – August 27, 2026 MBX Biosciences announced that the first patient has been dosed...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
AstraZeneca Reports Positive Phase III Results for Eneboparatide in HypoPT
PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...
Advertisement
